Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardica improved anastomosis technology:

This article was originally published in Clinica

Executive Summary

Cardica has received US FDA 510(k) clearance to market a new version of its automated anastomosis technology that it claims will give surgeons improved manoeuvrability when attaching blood vessels and grafts during coronary artery bypass graft (CABG) procedures. The device, called C-Port Flex A, is also expected to bring "the possibility of performing truly minimally invasive cardiac surgery" several steps closer, said the Redwood City, California firm. It features several modifications to Cardica's previous C-Port xA product: It has a flexible, rather than rigid, shaft; is effective in creating compliant anastomoses in vessels as small as one millimetre in diameter; and can be used in either on- or off-pump CABG procedures. Importantly, the device can be positioned to create a secure connection in the most difficult to reach areas of the heart, the firm added.

You may also be interested in...



Dr Reddy's Adds To OTC Portfolio With Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.

Sandoz Launches US Awareness Campaign

Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.

EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

Topics

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel